Sponsor
Gilead Sciences
49 PBAC submissions on file, active 2005–2025. 65% have been recommended.
Submissions
49
2005 → 2025
Win rate
65 %
32 recommended of 49 bucketable
Drugs
28 · 20 listed
unique molecules submitted
PBS spend captured
—
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Infectious disease 16 Hepatology 13 Oncology 8 Haematology 5 Gastroenterology 3 Respiratory 2 HIV/AIDS 1 Immunology 1
Activity by year 2005 (1) · 2006 (2) · 2007 (2) · 2008 (1) · 2009 (1) · 2010 (1) · 2011 (1) · 2012 (1) · 2013 (3) · 2014 (1) · 2015 (7) · 2016 (10) · 2017 (4) · 2018 (2) · 2019 (1) · 2021 (1) · 2022 (2) · 2023 (3) · 2024 (1) · 2025 (4)
Rejection patterns
Across 12 Not recommended decisions on file.
2× comparator in key trial not relevant to current PBS treatment algorithm1× Unclear clinical need for cobicistat as a single-ingredient product1× inadequate evidence to support non-inferior comparative effectiveness and safety claim1× no current place in published treatment guidelines outside of combination product Stribild1× trial population not consistent with proposed PBS population (all treatment-naïve)Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.